Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Endo Health Solutions Inc    ENDP

News SummaryMost relevantAll newsSector news 

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

share with twitter share with LinkedIn share with facebook
share via e-mail
05/01/2012 | 02:13pm CEST

Endo Pharmaceuticals Holdings Inc.'s (>> Endo Pharmaceuticals Holdings Inc) swung to a first-quarter loss, mostly owing to a $110 million charge related to a 2010 litigation settlement, while the pharmaceutical company reported revenue grew with a boost from a recent acquisition.

Endo has seen its revenue rise in recent quarters, aided by acquisitions that expanded its generic-drug business and core painkiller franchise. But the related charges have hurt its bottom line of late.

First-quarter sales were expected to be affected by a temporary shutdown of a Novartis AG (NVS, Z.NOV) plant in Nebraska to address potential packaging errors. The plant manufactures some Endo products such as its Opana ER painkiller. In the latest period, Opana ER sales were down 4.2%. On Tuesday the company said Opana ER and Voltaren Gel now in steady supply.

Endo reported a loss of $87.3 million, or 75 cents a share, compared with a year-earlier profit of $55.8 million, or 46 cents a share. Excluding impacts from a 2010 litigation settlement with Impax Laboratories Inc. (IPXL), adjusted earnings were down at 87 cents from $1. The company in February expected earnings below 90 cents amid a temporary shutdown at the Novartis plant.

Revenue increased 23% to $691 million, with a boost from its American Medical Systems acquisition. Analysts polled by Thomson Reuters most recently projected $702 million.

Gross margin fell to 47.2% from 58.7%.

Sales of Lidoderm, which makes up the biggest chunk of Endo's top line, were up 11%.

Overall branded drug sales were down 3% while generics sales increased 8%.

Shares of Endo, which reaffirmed its 2012 guidance, closed Monday at $35.14 and were inactive premarket. The stock is down roughly 10% in the past year.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Stocks mentioned in the article : Endo Pharmaceuticals Holdings Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
React to this article
06/28 ENDO INTERNATIONAL PLC : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC ..
06/24 ENDO INTERNATIONAL PLC : Pomerantz Law Firm Reminds Shareholders with Losses on ..
06/11 ENDO INTERNATIONAL PLC : INVESTIGATION ALERT: Lundin Law PC Announces Investigat..
06/10 ENDO INTERNATIONAL PLC : Levi & Korsinsky, LLP Notifies Shareholders of Endo Int..
05/27DJValeant Rejected Joint Takeover Approach From Takeda, TPG
05/17 ENDO INTERNATIONAL PLC : Bronstein, Gewirtz & Grossman, LLC Announces Investigat..
05/10DJU.S. Investigates Drugmaker Contracts With Pharmacy-Benefit Managers -- Updat..
05/10DJU.S. Investigates Drugmaker Contracts With Pharmacy Benefit Managers
05/06DJU.S. HOT STOCKS : Hot Stocks to Watch
Income Statement Evolution
More Financials